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Periodontal inflammation is one of the most common chronic inflammatory conditions
in humans. Despite recent advances in identifying and characterizing oral microbiota
dysbiosis in the pathogenesis of gum disease, just how host factors maintain a healthy
homeostatic oral microbial community or prevent the development of a pathogenic oral
microbiota remains poorly understood. An important determinant of microbiota fate is
local antimicrobial proteins. Here, we report that chemoattractant protein chemerin,
which we recently identified as a potent endogenous antimicrobial agent in body barriers
such as the skin, is present in the oral cavity under homeostatic and inflammatory con-
ditions. Chemerin and a chemerin-derived antimicrobial peptide are bactericidal against
select bacteria strategically positioned in dental biofilm. Gingival crevicular samples from
patients with gingivitis but not periodontitis contain abundant bioactive chemerin capa-
ble of inducing CMKLR1-dependent leukocyte migration. Gingipains secreted by the
periodontopathogen P. gingivalis inactivate chemerin. Together, these data suggest that
as an antimicrobial agent and leukocyte chemoattractant, chemerin likely contributes to
antimicrobial immune defense in the oral cavity.
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inTrODUcTiOn
Chemerin is a chemoattractant protein implicated in recruitment of dendritic cells (DCs), mac-
rophages, and NK cells to sites of inflammation (1). These immune cells express the G-protein-coupled 
signaling receptor CMKLR1, which mediates cell chemotactic responses to bioactive chemerin (2, 
3). Chemerin circulates as an inactive isoform (chemS163) and needs to be proteolytically processed 
to display chemotactic potential. Bioactive chemerin lacking six amino acids in the C-terminus 
(chemS157) has been isolated from body fluids (1), and various serine and cysteine proteases of host 
and microbial origin can generate active chemerin by C-terminal processing in vitro (4–6). However, 
proteases can also inactivate or degrade the attractant and thus limit the extent of chemerin activity 
(1). Chemerin is broadly expressed in numerous anatomic sites, including liver and fat tissues as 
well as by epithelial cells in the skin epidermis (7–10), intestinal epithelium (8, 11), and pulmonary 
Table 1 | Demographic and clinical data.
gingivitis (n = 6) Periodontitis 
(n = 15)
Age: mean (range) 46.3 (17–78) 63.9 (51–78)
Male/female (n) 1/5 5/10
Sites with PD ≥ 5 mm (n; 
mean ± SD)
0 10.7 ± 6.5
Sites with AL ≥ 5 mm (n; 
mean ± SD)
0.67 ± 1.03 23.1 ± 15.0
BOP (%; mean ± SD) 44 ± 15 39 ± 14
PI (%; mean ± SD) 62 ± 11 46 ± 20
PD, probing depth; AL, attachment loss; BOP, bleeding on probing; PI, plaque index.
2
Godlewska et al. Chemerin in Oral Cavity
Frontiers in Immunology | www.frontiersin.org March 2017 | Volume 8 | Article 353
airways (8, 12). The strategic positioning of chemerin at the host-
environment interface suggests a role in antimicrobial defense.
We recently demonstrated that human recombinant 
chemerin as well as endogenous chemerin secreted by primary 
human keratinocytes in organ cultures significantly inhibited 
growth of skin bacteria (6, 9). As is the case for chemoat-
tractant activity, the inhibitory C-terminal peptide present 
in the chemerin holoprotein chem163S must be removed for 
full antibacterial effects. An internal 20-amino acid peptide 
V66–P85 embodies most of the antimicrobial activity of active 
chemerin, and is comparable in potency to other antimicro-
bial peptides (AMPs) (9). Chemerin was recently reported 
to be present in the oral cavity, and the levels of chemerin in 
saliva and gingival crevicular fluid were increased in patients 
suffering from periodontitis (13, 14). Since periodontitis 
is associated with an imbalance of oral microbiota (15, 16), 
these findings together suggest that chemerin might influence 
disease processes through controlling bacteria burden and/or 
composition in the oral cavity and by regulating immune cell 
infiltration.
The human oral cavity harbors diverse microbes that 
colonize gingiva and teeth (15, 17). The majority of bacteria 
in the oral cavity are organized in a biofilm structure. Primary 
(early) colonizers mostly belong to Streptococcus genera 
represented by S. oralis, S. mitis, and S. sanguinis, three of the 
most prevalent species of streptococci that are able to attach 
to enamel and epithelial surfaces (18). The streptococci co-
aggregate with other bacteria species represented by many 
genera, including Prevotella spp. and Actinomyces spp. Since 
many primary colonizers lack specific adhesins required 
for coaggregation, assembly of a more diverse and larger 
community is promoted by specific bacterial species such as 
Fusobacterium nucleatum. Usually found in the middle layer of 
a biofilm, F. nucleatum coordinates the coaggregation of early 
and late colonizers (16). Notably, colocalization of F. nucleatum 
with so-called “red complex” pathogens, such as Treponema 
denticola, Porphyromonas gingivalis, and Tannerella forsythia 
(19), suggests that integration of these pro-inflammatory and 
tissue-destructive pathogens to dental plaque is F. nucleatum 
dependent (20–22).
The oral cavity, in common with other portals of microbe 
entry, contains a variety of AMPs that can restrict the growth 
of bacteria and prevent potential pathologic outcomes. Salivary 
glands, epithelial cells, and oral cavity-recruited neutrophils 
produce over 45 AMPs that are detected in saliva and gingival 
crevicular fluid. These include cathelicidins (LL37), α-defensins, 
β-defensins, histatins, and secretory leukocyte protease inhibi-
tor (SLPI) (23–26). Because AMPs utilize different strategies 
to restrict microbial growth (24, 27), their diversity may be 
important for independently controlling the load, composition, 
and location of microbial communities in the oral cavity and for 
maintaining oral homeostasis.
Here, we report that chemerin directly acts on specific oral bac-
teria strains and exhibits chemotactic activity in gingivitis patient 
samples. Together, these findings suggest that antimicrobial and 
chemoattractant chemerin can shape the oral microbiome and 
coordinate oral immune defense mechanisms.
MaTerials anD MeThODs
Materials
Chemerin peptide 4 (VRLEFKLQQTSCRKRDWKKP) (p4) and 
scramble peptide 4 (DPWLKVRKFQTLKQREKRCS) (scp4) 
were chemically synthesized by ChinaPeptide (Shanghai, China). 
Chemically synthesized LL37 was from Emory Microchemical 
Facility (Atlanta, GA, USA). Recombinant human full-length 
chemerin variant chem163S and chemerin variant chem157S, 
lacking 6 aa at C-terminus were produced in Pichia pastoris. 
DNA fragments corresponding to the desired chemerin proteins 
were amplified by PCR and cloned into the pPIC9K expression 
vector (Life Technologies, Carlsbad, CA, USA) using the overlap-
extension PCR method (28). Both constructs lacked the 20 aa 
chemerin signal peptide but had the hexahistidine tag (His-tag) 
and the enterokinase cleavage site added to their N terminus. 
The identity of created constructs was verified by sequencing 
(Genomed, Poland). Recombinant chemerin isoforms were pro-
duced using P. pastoris strain GS115 (His−), transformed with the 
SalI-linearized pPIC9-chemerin construct. Recombinant proteins 
were purified from the supernatants of His + transformants using 
Ni-Sepharose 6 Fast Flow (GE Healthcare, Uppsala, Sweden). 
The recombinant chemerin variants were eluted with 500  mM 
imidazole and dialyzed against phosphate buffered saline (PBS). 
The molecular weight and purity of the obtained proteins was 
determined by SDS-PAGE and Coomassie Blue staining. Since 
the final recombinant chemerin variants contained a His-tag, we 
also evaluated in parallel a His-tag free, HPLC-purified chemerin 
variant lacking 16 aa at the C-terminus, chem147S (1, 5), with 
similar results (data not shown). Recombinant human SLPI was 
produced as previously described (29).
human samples collection
Unstimulated whole saliva samples were collected from healthy 
volunteers [n = 15, male:female 5:10; age 28.5 ± 4.8 (21–36)]. The 
participants rinsed their mouth with water before the collection. 
Saliva samples were collected 10 min later and centrifuged twice 
(10,000 × g, 5 min) to remove cellular debris and stored at −80°C 
until used. Six patients with gingivitis and 15 patients with peri-
odontitis were recruited in a private dental practice. Demografic 
and clinical data of the patients are listed in Table 1. Subgingival 
plaque and tissue were sampled from the deepest site per quadrant 
(in case of the gingivitis patients from the mesio-buccal site of the 
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first molar) by inserting each an endodontic paper-point (ISO 
055) for 30  s into the pocket until resistance felt. Paper-points 
were pooled, transferred into a tube and RNAlater™ storage 
solution (Sigma-Aldrich) was added. Not earlier than 24 h later, 
gingival crevicular wash-out (GCF) was obtained as previously 
described (30). Immediately after sampling, paper-points were 
stored at −20°C and GCF samples at −80°C until assayed. The 
total protein concentration in saliva and GCF was determined 
by bicinchoninic acid assay (Sigma-Aldrich). The patients 
study protocol was approved by the Ethical Commission of the 
University of Leipzig. All subjects gave written informed consent 
in accordance with the Declaration of Helsinki.
Pcr
DNA and RNA was simultaneously extracted from the paper-points 
using innuPREP RNA/DNA mini kit (Analytic Jena AG) accord-
ing to the manufacturer’s instruction. DNA was used for real-time 
PCR analysis of the major periodontopathogens as previously 
described (31). RNA was converted to cDNA using the GoScript™ 
Reverse Transcription System (Promega) according to the 
manufacturers’ instructions. qPCR was performed using GoTaq® 
qPCR Master Mix (Promega) and primers specific for P. gingivalis 
proteases (32): rgpA, 5′-TATCCTTCGTGATGTGCGTG-3′, 
5′-GCTGTAACGGGAGAAGCAAT-3′; rgpB, 5′-CATTCTCCT 
CTCTGTTGGGA-3′, 5′-CGTAGGGGATTTGATCAGGA-3′; 
kgp, 5′-TCAAGCAGT CGATGCAAGC-3′, 5′-ACTTGGGTCAG 
TTCTTGTCC-3′; and sod, 5′-AATTCCACCACGGTAAGC 
AC-3′, 5′-TTCTCGATGGACAGTTTGCC-3′; as well as human 
chemerin 5′-TGGAAGAAACCCGAGTGCAAA-3′, 5′-AGAAC 
TTGGGTCTCTATGGGG-3′, and GAPDH, 5′-GACAGTCAGC 
CGCATCTTCT-3′, 5′-TTAAAAGCAGCCCTGGTGAC-3′. The 
relative gene expression normalized to sod (rgpA, rgpB, kgp) and 
GAPDH (chemerin) was calculated using the 2−ΔΔCT method (10, 
33, 34).
elisa
Chemerin levels in saliva and GCF samples were quantified by 
ELISA. Monoclonal mouse anti-human chemerin (R&D System) 
and biotin-labeled polyclonal goat anti human chemerin (R&D 
System) Abs were used to detect chemerin. HRP-labeled strepta-
vidin (BD Pharmingen) was used to bind the biotinylated Abs. 
The plate was developed with 3,3′,5,5′-Tetramethylbenzidine 
substrate (TMB) (BD Biosciences), stopped using 0.18M sulfuric 
acid and measured at 450 nm. Alternatively, commercially avail-
able chemerin ELISA kit (R&D Systems) was used according to 
the manufacturer’s recommendations.
bacterial strains and culture conditions
The bacterial strains used in this study were standard strains 
except Sov-A mutant with replacement of sov gene (PG0809/10) 
in Porphyromonas gingivalis W83 with a tetQ cassette (Tc 1 µg/ml, 
Sigma-Aldrich). P. gingivalis ATCC 33277 was cultured in Brain 
Heart Infusion broth (BHI) (Becton Dickinson) supplemented 
with yeast extract (5 g/l, Lab Empire), hemin (10 mg/l, Sigma-
Aldrich), l-cysteine (0.25 g/l, Lab Empire), menadione (0.5 mg/l, 
Sigma-Aldrich), and defibrinated sheep blood (5% v/v). P. gingi-
valis W83 and P. gingivalis Sov-A were cultured in Scheadler broth 
(BTL) supplemented with menadione (0.5  mg/l), defibrinated 
sheep blood (5% v/v). Prevotella intermedia 17, Fusobacterium 
nucleatum ATCC 10953, F. nucleatum ATCC 25586 were cultured 
in Trypticase soy broth (TSB) (Sigma-Aldrich) supplemented 
with defibrinated sheep blood (5% v/v). Tannerella forsythia 
ATCC 43037 was cultured in TSB supplemented with hemin 
(5 mg/l), N-acetyl muramic acid (10 mg/l, Sigma-Aldrich) and 
defibrinated sheep blood (5% v/v). Streptococcus salivarius ATCC 
7073, S. sanguinis ATCC 10556, S. oralis ATCC 35037, S. gordonii 
ATCC 10558 were cultured in BHI. P. gingivalis, P. intermedia, 
F. nucleatum, and T. forsythia were grown in an anaerobic 
atmosphere using a GasPak™ EZ Anaerobe Pouch System 
(BD). Streptococci were grown in a 5% CO2 atmosphere using a 
GasPak™ EZ CO2 Pouch System (BD).
Microdilution assay (MDa)
Overnight cultures of bacterial strains were sub-cultured to 
fresh media and grown to mid-logarithmic phase. Bacteria were 
harvested, washed three times with Dulbecco’s PBS and diluted 
to 4 × 105 CFU/ml with PBS. Bacteria were then incubated for 3 h 
with either p4 at 100 µM or scp4 (negative control) at 100 µM. 
LL37 (50 µg/ml) was used as a positive control.
Minimal inhibitory concentration (Mic) 
Determination
Minimal inhibitory concentration was determined as previously 
described (35) with some modifications. Briefly, bacteria were 
prepared as described above and diluted to 4 × 106 CFU/ml with 
0.2% bovine serum albumin in PBS. Series of twofold dilution of 
peptide p4 were prepared in PBS to provide final concentration 
range 400–0.4 µg/ml (154–0.15μM). Bacterial suspensions were 
mixed with p4 or PBS (control) and incubated at 37°C overnight. 
The MIC was defined as the lowest antimicrobial concentration 
which prevented visible growth of bacteria.
biofilm Formation
Overnight bacterial cultures were harvested, washed with PBS 
and adjusted to OD600nm = 1. One hundred microliters of bacte-
rial suspension previously diluted 1:100 in BTL supplemented 
with menadione (0.5 mg/l) were grown in flat-bottomed 96-well 
polystyrene microplates (Sarstedt) under anaerobic condition. 
After incubation for 48 h, supernatant containing planktonic cells 
and media was gently removed and replaced with p4 (100 µM) 
in PBS or PBS alone (control). The viability of the bacterial cells 
in biofilm after 5 h treatment with p4 was determined using The 
BacTiter-Glo™ Microbial Cell Viability Assay (Promega) based 
on ATP-based luminescence quantification. The number of viable 
bacteria was conducted by counting CFU/ml. Following the 
incubation with p4, biofilms were resuspended, serially diluted 
and plated on an agar medium.
Protease activity assay
Overnight cultures of P. gingivalis W83 strain were adjusted to 
OD600nm = 1 with BTL and centrifuged for 15 min at 6,000 × g. The 
conditioned media were harvested and stored at 4°C until used. 
Conditioned media and GCF samples were tested for protease 
Table 2 | Microbiological and chemerin expression data in gingival samples from patients with peridontal disease.
gingivitis n = 6 Periodontitis n = 15
Positive samples with 
bacteria loads ≥ 105  
(n/total)
Median [interquartile 
range] × 105
Positive samples with 
bacteria loads ≥ 105  
(n/total)
Median [interquartile 
range] × 105
p (Mann–
Whitney)
A. actinomycetemcomitans 1/6 0.00 [0.00; 3.44] 7/15 0.00 [0.00; 2.97] 0.340
P. gingivalis 5/6 0.07 [0.01; 3.84] 13/15 1.03 [0.51; 2.10] 0.029*
T. forsythia 4/6 1.13 [0.00; 16.9] 15/15 1.66 [0.39; 33.3] 0.080
T. denticola 3/6 0.22 [0.00; 1.32] 6/15 0.00 [0.00; 0.11] 0.340
Positive samples  
(n/total)
Median [interquartile 
range] × 105
Positive samples  
(n/total)
Median [interquartile 
range] × 105
rgpA RNA relative to sod 1/6 0.00 [0.00; 0.45] 12/15 0.35 [0.02; 2.57] 0.023*
rgpB RNA relative to sod 1/6 0.00 [0.00; 3.16] 12/15 0.76 [0.22; 3.38] 0.045*
kgp RNA relative to sod 1/6 0.00 [0.00; 2.77] 12/15 0.52 [0.26; 158.3] 0.023*
Chemerin mRNA relative to 
GAPDH
5/6 0.33 [0.00; 1.63] 13/15 1.04 [0.31; 1.93] 0.205
Positive samples  
(n/total)
Median [interquartile  
range]
Positive samples  
(n/total)
Median [interquartile range]
Chemerin protein (ng/mg 
total protein)
6/6 4.37 [0.43; 17.84] 15/15 6 [2.81; 10.30] 0.340
*Statistically significant.
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activity using Nα-Benzoyl-l-Ala 4-nitroanilide hydrochloride 
and N-(p-Tosyl)-Gly-Pro-Lys 4-nitroanilide acetate salt (both 
from Sigma) hydrolyzed by Rgp and Kgp gingipains, respectively. 
Ten microliters of bacterial conditioned media (corresponding 
to 107 CFU) or 4 µl GCF samples (each containing 48 µg of total 
protein) were diluted with TNC buffer (200 mM Tris, 150 mM 
NaCl 5 mM CaCl2 pH = 7.6) with 10 mM l-cysteine to a final 
volume of 100 µl (for bacterial supernatants) or 50 µl (for GCF). 
To inhibit gingipains, 1 µM of either KYT–1 (RgpA and RgpB-
specific inhibitor) or KYT–36 (Kgp-specific inhibitor) (36), were 
added. The mixtures were then preincubated for 20 min at 37°C. 
Equal volume of Rgp or Kgp substrate diluted in TNC buffer was 
then added to final substrate concentration of 1 mM and final 
volume of either 100 or 200  µl. The increase of absorbance at 
λ = 405 nm as a measure of hydrolyzed substrate was recorded for 
at least 90 min at 37°C, using a microplate reader (Tecan Infinite 
M200).
chemotaxis assay
GCF samples from gingivitis and periodontitis patients were 
tested in an in vitro chemotaxis assay using 5 µm pore Transwell 
inserts (Costar) and murine pre-B lymphoma cell line L1.2 or 
L.1.2 cells stably transfected with human recombinant CMKLR1 
(CMKLR1/L1.2). Chemotaxis assay was performed using 
chemotaxis media [RPMI 1640 w/l-glutamine supplemented 
with 25  mM HEPES (Biowest) and 10% FBS (Gibco)]. One 
hundred microliters of cells (2 × 105 cells/well) were added to the 
top well and tested samples, each containing 1 nM of chemerin 
(as determined by ELISA) were added to the bottom well in 
a 600  µl volume. Migration was assayed for 2  h at 37°C. The 
inserts were then removed and cells that had migrated through 
the filter to the lower chamber were collected and counted by 
flow cytometry (LSRII, BD). The results are presented as% input 
migration.
chemerin Processing by gingipains
Ten microliters of conditioned media derived from overnight 
cultures of P. gingivalis W83 (corresponding to 107 CFU) were 
mixed with 5 µl of TNC buffer with 10 mM l-cysteine. For inhibi-
tion test, KYT-1 and KYT-36 were added to a final concentration 
of 1  µM. The samples were preincubated for 20  min at 37°C, 
followed by overnight incubation with 50  ng human recombi-
nant chemS157. The samples were then analyzed in an in vitro 
chemotaxis assay.
resUlTs
To determine whether chemerin serves as AMP against oral 
bacteria, we first analyzed chemerin protein levels in saliva of 
healthy individuals with no signs of periodontal disease. In 
agreement with a recent report (13), chemerin was found in 
saliva from healthy donors, in the concentration of 1.3 ± 0.5 ng/
mg total protein (mean ±  SD, n =  15). Next, we determined 
chemerin RNA and protein levels in gingiva samples from 
patients suffering from periodontal inflammation. We analyzed 
samples from patients with either gingivitis (gum inflamma-
tion) or periodontitis, a more severe form of gum disease 
associated with progressive alveolar bone loss around the teeth. 
Donor demographics and clinical parameters are included in 
Table 1.
As anticipated, periodontitis patients presented with signifi-
cantly elevated colony counts of the periodontopathogen P. gin-
givalis and its associated gingipain proteases (RgpA, RgpB, and 
Kgp) compared to patients with gingivitis (Table 2). Chemerin 
Table 3 | correlation of chemerin gene expression and chemerin protein 
levels with clinical and microbiological variables (P and R are only given 
if p was statistically significant) spearman rho.
chemerin expression
R P
PD ≥ 5 mm (n) 0.472 0.031
AL ≥ 5 mm (n) 0.451 0.034
BOP (%) n.s.
PI (%) n.s.
A. actinomycetemcomitans n.s.
P. gingivalis 0.462 0.035
T. forsythia 0.550 0.010
T. denticola n.s.
Chemerin protein level n.s.
PD, probing depth; AL, attachment loss; BOP, bleeding on probing; PI, plaque index; 
n.s., not significant.
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gene expression tended to be higher in periodontal region samples 
from the periodontitis group compared to gingivitis, although 
the difference was not statistically significant (Table 2). Likewise, 
GCF samples from gingivitis and periodontitis patients contained 
on average similar levels of chemerin (5.6 ± 1.3 ng/mg of total 
protein vs. 6.3 ± 1.1 ng/mg, mean ± SEM) and Table 2. While 
there were no significant correlations between chemerin protein 
levels and the examined clinical/microbiological variables (data 
not shown), there was a significant positive correlation between 
chemerin gene expression and clinical probing depth and attach-
ment loss measurements as well as abundance of P. gingivalis 
and T. forsythia in the pocket samples (Table 3). Together these 
data suggest that chemerin may be involved in the regulation of 
microbiota in the oral cavity under both homeostatic and inflam-
matory conditions.
We next explored whether chemerin exhibits antimicrobial 
activity against selected oral bacterial species that are differently 
located in oral biofilm and differ in pathogenic potency. Since 
chemerin peptide 4 (p4), corresponding to the internal Val66–Pro85 
region of human chemerin, is primarily responsible for chemerin 
antimicrobial effects (9), we tested selected components of the oral 
microbiota for sensitivity to p4 by MDA assay. This assay detects 
the planktonic (free floating) form of bacteria. Scramble peptide 
4 (scp4, 100  µM) and oral antimicrobial agent LL37 (11  µM) 
(24), were used as a negative and positive controls, respectively. 
Chemerin peptide p4 (100 µM) completely inhibited the growth 
of two out of four tested Streptococcus species, S. salivarius ATCC 
7073 and S. sanguinis ATCC 10556, but not S.  gordonii ATCC 
10558 or S. oralis ATCC 35037. In contrast, LL37 completely 
inhibited the growth of S. gordonii ATCC 10558 but not S. oralis 
ATCC 35037 (Figure  1). Peptide p4 also completely inhibited 
the growth of two different strains of F. nucleatum; F. nucleatum 
ATCC 10953 and ATCC 25586. However, the growth of P. inter-
media 17 or the red complex constituent T. forsythia (T. forsythia 
ATCC 43037) was not inhibited by p4, although they were largely 
susceptible to LL37-dependent growth inhibition (Figure  1). 
Likewise, only slight but significant inhibition of another red 
complex component P. gingivalis was noted, leading to survival of 
78 ± 9% of bacteria compared to the vehicle-treated P. gingivalis 
ATCC 33277 (set as 100%) or to the scramble p4 peptide control 
(118  ±  17%). The growth/viability of two other P. gingivalis 
strains (W83 and SOV) was not suppressed by p4, although LL37 
significantly inhibited their growth (Figure 1). In contrast to p4, 
scp4 did not limit the growth of the tested strains, and in some 
cases even increased the number of viable counts of bacteria 
(Figure 1). The differential anti-microbial activity of p4 against 
oral bacteria was further demonstrated by MIC values, which 
were 50 µg/ml (19.2 µM) for the most sensitive Streptococci and 
F. nucleatum strains, and 400 µg/ml or more for less sensitive and 
resistant strains (Figure 2). We conclude that chemerin peptide 4 
has the ability to limit the growth of specific oral cavity-resident 
bacteria, but exhibits variation in its ability to kill different species 
of oral microbes.
Next, we tested whether chemerin isoforms, either full-length, 
chemotactively inert chemS163, or the truncated, chemotactively 
active chemS157 (both containing the internal p4 sequence) 
affect the growth of p4-sensitive F. nucleatum and largely resist-
ant P. gingivalis. Both chemS163 and chemS157 significantly 
suppressed the growth of F. nucleatum ATCC 25586 at 2µM 
(67 ± 23 and 62 ± 26% viability, mean ± SD, compared with con-
trol); however, their inhibitory effects were less robust than 2µM 
p4 (16 ± 3%) (Figure 3). On the other hand, neither chemerin 
isoforms showed significant antimicrobial activity against P. gin-
givalis ATCC 33277 (Figure 3). These data suggest that not only 
chemerin-derived peptide 4 but also full-length chemerin and 
its endogenous bioactive isoform inhibit the growth of selected 
oral bacteria.
To evaluate potential additive or synergistic effects between 
chemerin and other oral AMPs, we next tested the antimicrobial 
activity of combinations of p4 with LL37 and SLPI. AMPs were 
tested at suboptimal concentrations that resulted in >30 and 
<90% growth inhibition when applied alone, based on previously 
determined MIC values for each AMP (Figure  2 and data not 
shown). Chemerin peptide p4 (2.5 µg/ml) given in combination 
with LL37 (2.5 µg/ml) and/or SLPI (10 µg/ml), in each case was 
significantly more bactericidal against S. salivarius and F. nuclea-
tum than each agent given alone (Figure 4). These data suggest 
that all three AMPs cooperate for optimal restriction of bacterial 
growth in oral cavity.
The majority of bacteria in the oral cavity grow attached to the 
teeth and epithelial surfaces as biofilm components. Therefore, 
we next determined whether p4 inhibits the attached forms of 
F. nucleatum and P. gingivalis, in addition to suppressing the 
planktonic form of the bacteria (Figure 1). F. nucleatum and P. 
gingivalis were cultured for 48  h under biofilm-like conditions 
and then treated with p4 or vehicle PBS for 5 h. The growth of the 
attached form of F. nucleatum was markedly suppressed by p4 
(Figure 5). In contrast, P. gingivalis was resistant to p4 treatment 
(Figure 5). These data suggest that chemerin exerts antimicro-
bial activity during either biofilm or planktonic life cycles of F. 
nucleatum but is minimally or not effective against planktonic 
and biofilm form, respectively, of P. gingivalis.
Since chemerin is chemoattractant for immune cells that are 
implicated in the pathogenesis of periodontal disease, including 
DCs, macrophages, and NK cells (37–41), we next tested whether 
chemerin in GCF samples from individuals with gingivitis and 
FigUre 1 | selective antimicrobial activity of chemerin peptide p4 against oral bacteria. Chemically synthesized chemerin p4 and scramble p4 (scp4) 
peptides as well as LL37 were tested against the indicated oral cavity bacterial strains using MDA assay. Bacteria were incubated with p4 and scp4 at 100 µM, and 
LL37 at 11 µM for 3 h. The results are expressed as the mean ± SD of three independent experiments. ***p < 0.001, **p < 0.01, *p < 0.05 by Kruskal–Wallis 
one-way ANOVA with post Dunn’s test for multiple comparison, comparing vehicle treated bacteria (control) and the peptide-treated bacteria, or p4 vs. scp4.
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periodontitis is able to support chemotaxis of chemerin respon-
sive CMKLR1+ cells. We performed in vitro transwell chemotaxis 
assays using the GCF samples each containing 1 nM endogenous 
chemerin (as determined by ELISA) and 1 nM bioactive chemS157 
as a positive control. CMKLR1-transfected L1.2 cells migrated 
to GCF from gingivitis patients (4.2%) but showed little migra-
tion to GCF from periodontitis individuals (0.5%) (Figure 6A). 
When CMKLR1-negative parental L1.2 cell were used instead of 
CMKLR1/L1.2 transfectants, very little chemotaxis was detected 
(Figure 6A). These data indicate that the observed response was 
chemerin-dependent.
Since GCF samples from the gingivitis and periodontitis 
groups contained similar levels of chemerin (Table 2) but mark-
edly differed in the attractant activity (Figure 6A), these data 
suggest that chemerin is inactivated in periodontitis patients, 
possibly by factors secreted by periodontal pathogens. The 
possible candidates include P. gingivalis-produced gingipains 
(RgpA, RgpB, and Kgp) (Table 2). To determine whether these 
proteases inactivate chemerin, P. gingivalis conditioned media 
were incubated with recombinant chemS157. The involvement 
of gingipains in chemerin inactivation was examined using 
conditioned media in which these enzymes were blocked 
by gingipain-specific inhibitors prior to incubation with 
chemS157. As shown in Figure 6B, CMKLR1-transfected L1.2 
cells migrated robustly in response to chemS157, but almost 
no migration was noted when chemS157 was treated with P. 
gingivalis conditioned media. The effect of the conditioned 
media was largely reversed by gingipain-specific inhibitors, 
indicating that gingipains inactivate the chemoattactant activity 
of chemerin.
DiscUssiOn
Chemerin is expressed by many different epithelial tissues and 
plays a role in skin immune defense (1, 9, 10). Here, we demon-
strate that chemerin is also expressed in the oral cavity, where it 
FigUre 3 | chemerin isoforms chems163 and chems157 exhibit 
antibacterial activity against F. nucleatum but not P. gingivalis. The 
antimicrobial activity of chemerin isoforms chemS163, chemS157 (both at 
2µM), and p4 at 2µM were tested against F. nucleatum ATCC 25586 and P. 
gingivalis ATCC 33277 using MDA assay. The results are expressed as the 
mean ± SD of three independent experiments. ***p < 0.001, **p < 0.01, 
*p < 0.05 by Kruskal–Wallis one-way ANOVA with post Dunn’s test for 
multiple comparison, comparing vehicle treated bacteria (control), and the 
peptide-treated bacteria.
FigUre 2 | Minimal inhibitory concentration (Mic) values for indicated oral cavity microorganisms. Data indicate% of killing for the indicated strain. The 
MIC was defined as the lowest concentration of p4 showing no visible growth (100% of killing). Mean ± SD of three independent measurements is shown.
7
Godlewska et al. Chemerin in Oral Cavity
Frontiers in Immunology | www.frontiersin.org March 2017 | Volume 8 | Article 353
likely contributes to antibacterial defense as an antibacterial agent 
and as a chemoattractant for immune cells. Using human samples, 
we showed that chemerin mRNA and protein is present in tissue 
cavity samples of individuals with inflammatory gum disease, and 
that chemerin protein is present in the saliva of healthy donors. 
Both planktonic and attached cultures of bacteria that specifi-
cally inhabit the oral cavity were sensitive to chemerin-derived 
peptide-p4 and chemerin protein isoforms. Thus, the physiologi-
cal role of chemerin in the oral cavity might be to directly mold 
the microbiome. Furthermore, chemerin present in GCF from 
gingivitis patients retained leukocyte chemoattractant activity 
rendering it uniquely suited to position DCs, macrophages, and/
or NK cells to sites of gum inflammation, where they may provide 
immune protection.
Our findings add chemerin to the list of potential endogenous 
oral AMPs. However, in contrast to other antimicrobial agents, 
such as LL37, chemerin exhibited a rather narrow spectrum 
of activity against oral microbiota (Figures  1 and 2). Among 
inhabitants of the periodontal biofilm, only Streptococcus spe-
cies and most notably F. nucleatum strains were identified as 
p4 targets. Several P. gingivalis strains, including SOV were not 
inhibited by p4. Given that the P. gingivalis SOV strain is defec-
tive in secretion of gingipains (42), these data suggest that that 
resistance of P. gingivalis to p4 is not due to degradation of p4 by 
these enzymes. This differential ability of either p4 or chemerin 
to inhibit the growth of oral bacterial strains suggests that 
chemerin is not a direct chemical shield against pathogens but 
rather serves to shape the oral microbial ecology. By acting on a 
defined spectrum of microbes, chemerin might limit an assembly 
of a disease-provoking microbiota. For example, the presence of 
chemerin-sensitive F. nucleatum benefits the entire community 
of bacterial inhabitants in subgingival plaque due to its unique 
ability to cooperate with other bacterial species in biofilm forma-
tion (16). Recent reports associate periodontal pathogenicity 
with an imbalance in microbiota, known as dysbiosis (15, 43, 
44). Therefore, through curtailing expansion of F. nucleatum, 
chemerin may help to maintain balance in the resident microbial 
community.
In common with other AMPs, chemerin in saliva or the GCF 
samples was found in less-than-effective concentrations to exert 
bactericidal effect on its own [Table  2; Figure  2; (13, 14, 24)]. 
FigUre 5 | Peptide p4 suppresses growth of F. nucleatum in biofilm in vitro. F. nucleatum ATCC 25586 and P. gingivalis W83 were grown attached in 
polystyrene microplates for 48 h followed by the incubation with 100 µM p4 or vehicle (PBS) for 5 h. The viability of bacteria was then determined by ATP-based 
luminescence quantification (a) or CFU counting (b).The results are shown as % of control (vehicle treated bacteria) and are expressed as the mean ± SD of five 
independent experiments. ***p < 0.001, by t test, comparing vehicle vs. p4 for each bacteria.
FigUre 4 | Peptide p4 cooperates with ll37 and secretory leukocyte protease inhibitor (slPi) in limiting growth of specific oral bacteria. Chemically 
synthesized peptides, p4 and LL37 as well as recombinant human SLPI were tested against indicated oral cavity bacterial strains using MDA assay. Bacteria were 
incubated with 2.5 µg/ml p4 and LL37, and 10 µg/ml SLPI for 3 h. The results are expressed as the mean ± SD of three independent experiments. *p < 0.05, 
**p < 0.01, ***p < 0.001, ns, not significant by Kruskal–Wallis one-way ANOVA with post Dunn’s test for multiple comparison.
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Since chemerin levels at oral infection sites are likely to be higher 
than in CGF wash outs, local chemerin may be present in suf-
ficient quantities to control oral microbiota by itself. However, 
chemerin may be more effective as an oral AMP by acting in 
concert with other antimicrobial agents. This is in-line with our 
findings showing additive inhibitory effects of p4, LL37, and SLPI 
on the growth of oral bacteria.
Certain AMPs serve a second role in host defense as leuko-
cyte attractants, and chemerin has the capacity to play a similar 
dual role in the oral cavity. Chemerin-mediated chemotaxis, 
FigUre 6 | gcF samples from gingivitis and periodontitis patients differ in chemerin-mediated chemotactic activity, and bioactive chems157 is 
inactivated in gingipain-specific manner. (a) Chemotactic bioactivity of endogenous chemerin from gingivitis (Gingiv) and periodontitis (Per) samples, each 
containing 1nM endogenous chemerin as determined by ELISA was evaluated by in vitro CMKLR1/L1.2 cell or L1.2 parental cell migration. Data are from one 
experiment, showing two combined samples in each patient group, and are representative of two experiments and five patients in each group. Migration to bioactive 
recombinant chemS157 at 1nM, and chemotaxis medium (Med) is shown as a positive and negative control, respectively. (b) 1nM recombinant chemS157 was 
incubated with the conditioned media from P. gingivalis W83 (P. gingiv. sup). Where indicated the media were first treated with gingipain-specific inhibitors 
(KYT-1 + KYT-36), followed by incubation with chemS157. The samples were tested in chemotaxis using CMKLR1/L1.2 transfectants. The mean ± SD from three 
experiments is shown. ***p < 0.001, *p < 0.05 by one-way ANOVA with post hoc Tukey Unequal N HSD test.
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exhibited by the gingivitis samples (Figure  6A), may serve to 
enhance the recruitment of CMKLR1+ cells to inflamed gums. 
CMKLR1+ DCs, macrophages, and NK cells have been associ-
ated with inflammatory gum disease and reported to infiltrate 
the inflamed gingiva (37–41). Although their role in gingivitis 
or periodontitis is not well defined, they are considered to be 
a part of the defense mechanism against microbial challenge 
in dental biofilm (37–41). However, since the innate immune 
response to microbes can lead to excessive inflammation and 
its associated damaging effects on healthy host tissue, these cells 
may also contribute to the pathogenesis of periodontal disease 
(37–41). In contrast to gingivitis, periodontitis is associated with 
a marked reduction in chemerin bioactivity (Figure 6A). These 
data suggest that the chemoattractant is locally functionally 
compromised in patients with periodontitis. Several lines of 
evidence support the role for gingipains in chemerin inactivation: 
(1) mRNA encoding all three gingipains (RgpA, RgpB, and Kgp) 
was present in higher levels and in a larger number of patients 
with periodontitis compared with individuals with gingivitis 
(Table 2); and (2) P. gingivalis supernatants inactivated chemS157 
in the gingipain-dependent manner (Figure  6B). However, in 
contrast to P. gingivalis conditioned media, we were not able to 
detect gingipain-specific enzymatic activity in GCF samples from 
either gingivitis or periodontitis individuals, which may be related 
to the substantial dilution (100–200×) of the wash samples (data 
not shown). Nevertheless, these data suggest that chemS157 is 
a novel gingipain substrate and that periodontal pathogens may 
utilize gingipains to subvert chemerin-dependent antimicrobial 
defense mechanisms.
Previous studies reported significantly higher levels of 
chemerin in saliva from periodontitis patients compared with 
gingivitis patients and healthy controls (13), and in GCF samples 
from periodontitis patients compared with healthy controls (14). 
Although in our studies we did not directly compare chemerin 
levels in saliva or GCF samples within the same groups of patients, 
chemerin levels were similar in GCF samples from periodontitis 
and gingivitis patients, with a trend for highler levels in the 
periodontitis group (Table 2). Chemerin is subject to posttransla-
tional regulation by proteolytic processing, and chemerin protein 
levels might be altered by degrading proteolytic enzymes present 
in inflamed tissues. Likewise, local degradation of chemerin 
by proteases such as gingipains in samples from periodontitis 
patients might also explain why, despite a positive correlation 
between chemerin gene expression in the pocket samples and the 
clinical and microbial variables, chemerin protein levels were not 
similarly correlated (Table 3).
Increased levels of bioactive chemerin are present in gingi-
vitis patient samples as opposed to periodontitis and thus are 
associated with less-severe gum disease. This broadly supports 
a protective role for chemerin signaling in the oral cavity. One 
of the possible mechanisms underlying bioactive chemerin-
mediated protection might involve production of antimicrobial 
agents by the infiltrating cells. Macrophages as well as NK cells 
are well-known to produce a variety of bactericidal compounds, 
including AMPs (45), and these agents might play an important 
role in containing infection. On the other hand, chemerin inac-
tivation might help to limit excessive inflammation and tissue 
destruction, including bone loss observed during periodontitis. 
This is supported by findings that chemerin is a negative regula-
tor of bone formation. Chemerin or CMKLR1 knock down in 
bone marrow-derived osteoblast precursor cells is associated 
with osteoblastogenesis (46). Since an imbalance between 
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bone-forming osteoblast and bone-resorbing osteoclast is the 
underlying cause of bone loss in periodontitis (47), disrup-
tion of chemerin-mediated signaling may promote osteoblast 
development.
In summary, chemerin has the ability to directly and selectively 
destroy oral microbes and may therefore influence the incidence 
or progression of gum disease via altering the composition of 
the oral microbiome. In addition, through guiding immune cells 
to infection sites, chemerin may help to translate the signals of 
microbial insult to a host physiological response. Inactivation of 
chemerin in periodontal lesions might lead to the immune dys-
regulation. Alternatively, chemerin inactivation might represent 
a mechanism to suppress deleterious inflammation and bone loss 
that characterizes periodontitis.
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